Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,

Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet

 44

 TERMINÉ 

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Voir le projet

 34

 TERMINÉ 

Adverse Immune Signatures and their Prevention in Corneal Transplantation (VISICORT)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2019,

"Immune system response is the most complex barrier to long-term success of tissue transplants/implants from allogeneic and bio-artificial sources. While newly developed tissue transplant procedures are not yet performed frequently enough for robust analysis of adverse immune responses in humans, corneal transplantation (CT) is a well-established allogeneic tissue transplant with >100,000 full- an ...
Voir le projet

 12

 TERMINÉ 

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer (GANNET53)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2019,

"Epithelial ovarian cancer (EOC) is the most lethal gyncaecological malignancy causing 41900 deaths annually in Europe. The predominance of aggressive Type II tumours, which are characterised by a high frequency of p53 mutations, and primary or acquired resistance to platinum-based chemotherapy profoundly contribute to the high mortality rate. With current standard therapy the median overall survi ...
Voir le projet

 20

 TERMINÉ 

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases (PRECISESADS)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therape ...
Voir le projet

 30

 TERMINÉ 

Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system (NEUROPAIN)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,

Neuropathic pain has a high incidence in Europe and often affects the patient’s emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patients and are limited by serious side effects. The search for new analgesics is extremely difficult despite identification of several new potential targets and enormous inv ...
Voir le projet

 12

 TERMINÉ 

PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood (PANCARELIFE)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The ...
Voir le projet

 19

 TERMINÉ 

Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex (EPISTOP)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of epilepsy is highest in infancy and 50% of children experience epilepsy-related comorbidities, such as developmental delay and autism. The development of epilepsy (epileptogenesis), extensively studied in animals, is barely studied in humans, as patients usual ...
Voir le projet

 16

 TERMINÉ 

Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy (DESIRE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

DESIRE will focus on epileptogenic developmental disorders EDD, i.e. early onset epilepsies whose origin is closely related to developmental brain processes. A major cause of EDD are malformations of cortical development (MCD), either macroscopic or subtle. EDD are often manifested as epileptic encephalopathies (EE), i.e. conditions in which epileptic activity itself may contribute to severe cogni ...
Voir le projet

 29

 TERMINÉ 

Systems biology for the functional validation of genetic determinants of skeletal diseases (SYBIL)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

"The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the age related factors contributing to these painful conditions. To achieve this goal SYBIL will gather complementary translational and transnational scientists, systems biologists, disease modellers, leading SMEs and industrialists that will perform in-depth char ...
Voir le projet

 19

 TERMINÉ 

Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology (BETACURE)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,

Background:Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptabl ...
Voir le projet

 17

 TERMINÉ 

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria (PRIORITY)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2017,

Patients with diabetes are at risk of developing diabetic nephropathy, which will ultimately result in the requirement for renal replacement therapy and is also associated with high cardiovascular morbidity and mortality. Detection of low concentrations of albuminuria in urine (microalbuminuria) is the current clinical standard for detecting those at significant risk and targeting preventive treat ...
Voir le projet

 21

 TERMINÉ 

Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation (BIO-DrIM)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. H ...
Voir le projet

 17

 TERMINÉ 

A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation (THE ONE STUDY)

Date du début: 1 nov. 2010, Date de fin: 31 oct. 2017,

Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. Reducing the need for immunosuppression would dramatically improve the outcome for transplant recipients and reduce health costs for society. The means to achieve this goal has not been realised with pharmacological or ...
Voir le projet

 16

 TERMINÉ 

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Voir le projet

 38

 TERMINÉ 

Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope (EU-CERT-ICD)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

An estimated 500.000 sudden cardiac deaths (SCD) occur each year in the European Union. Patients at risk for SCD may benefit from prophylactic treatment with an implantable cardioverter-defibrillator (ICD). ICD implantations have dramatically increased in recent years leading to multi-billion Euros of costs with significant regional disparities across Europe. Information on risks, benefits and cos ...
Voir le projet

 27

 TERMINÉ 

Clinical and system –omics for the identification of the MOlecular DEterminants of established Chronic Kidney Disease (iMODE-CKD)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

iMODE-CKD integrates multi-disciplinary expertise in proteomics, metabolomics, transcriptomics, bioinformatics, pathology, and clinical science from leading academic and industrial investigators, establishing a unique training platform on biomarker research and Systems Biology. Special emphasis is placed on the application of a wide range of –omics and bioinformatics techniques to clinical researc ...
Voir le projet

 10

 TERMINÉ 

VitaminD3-Omega3-Home Exercise- HeALTHy Ageing and Longevity Trial (DO-HEALTH)

Date du début: 1 janv. 2012, Date de fin: 30 juin 2017,

As the European population is ageing rapidly, the growing number of seniors with age-related chronic diseases poses a challenge on European societies and health care systems. Therapeutic interventions that are effective, affordable and well-tolerated in the prevention of chronic disease are urgently needed and will have an outstanding impact on public health as a whole. Among the most promising in ...
Voir le projet

 25

 TERMINÉ 

Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD) (DSD-LIFE)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

Disorders of sex development (DSD) are a conglomerate of rare diseases with an estimated incidence of 1: 4500. The causes of DSD are mainly disorders with gonadal dysgenesis, decreased androgen synthesis or function in XY males or disorders with elevated androgen production in XX females. Decision on sex of rearing is difficult in some cases as the prenatal androgen imbalances result in ambiguous ...
Voir le projet

 17

 TERMINÉ 

BeTheCuRE (BTCURE)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Voir le projet

 41

 TERMINÉ 

WATCHME Workplace-based e-Assessment Technology for Competency-based Higher Multi-professional Education (WATCHME)

Date du début: 1 mars 2014, Date de fin: 28 févr. 2017,

Continuing education at the workplace has seen increasing demand as a crucial means of acquiring the requisite professional knowledge and skills. Electronic Portfolios (e-portfolios) for workplace training provide a global view of each trainee's progress but offer no dynamic feedback to exploit the rich learning assessment data that could be analysed to support responsive adaptation for more effi ...
Voir le projet

 11

 TERMINÉ 

Integrated Approaches to Food Allergen and Allergy Risk Management (IFAAM)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,

Up to 20 million European citizens suffer from food allergy. However management of both food allergy (by patients and health practitioners) and allergens (by industry) is thwarted by lack of evidence to either prevent food allergy developing or protect adequately those who are already allergic. iFAAM will develop evidence-based approaches and tools for MANAGEMENT of ALLERGENS in FOOD and integrate ...
Voir le projet

 46

 TERMINÉ 

European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EuroHYP-1)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet

 38

 TERMINÉ 

IMmune MOdulating strategies for treatment of MErkel cell Carcinoma (IMMOMEC)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,

"Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of the skin associated with the recently discovered, common Merkel cell polyomavirus (MCV). With an incidence of 0.44 per 100,000 MCC is a very rare cancer. Notably, however, although MCC is 40 times less common than malignant melanoma, MCC has a dramatically higher mortality rate than melanoma rendering MCC to ...
Voir le projet

 11

 TERMINÉ 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Voir le projet

 22

 TERMINÉ 

European Bank for induced pluripotent Stem Cells (EBISC)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Voir le projet

 30

 TERMINÉ 

Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)

Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Voir le projet

 24

 TERMINÉ 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet

 34

 TERMINÉ 

Analysing Intravital Neuronal Protein Interactions in Metabolism and Apoptosis (AINIGMA)

Date du début: 1 nov. 2014, Date de fin: 31 oct. 2016,

"The high energy demand of the brain predisposes it to a variety of diseases if energy supplies are interrupted. Neurons are particularly intolerant of inadequate energy supply and die or degenerate in either an acutely or chronically disturbed metabolic environment.Although neurodegenerative diseases are classically not considered to be caused by disturbed metabolism, bioenergetic defects are eme ...
Voir le projet

 1

 TERMINÉ 

Repair of Diabetic Damage by Stromal Cell Administration (REDDSTAR)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

50 million diabetic EU citizens are using approved anti-diabetic agents to control their glycaemia. However, suboptimal glycemic control leads to 6 progressive diabetic complications, namely: nephropathy, retinopathy, cardiomyopathy, neuropathy and foot ulceration. In 2010, 11% of EU adult deaths (634,000) were caused by diabetic complications. These distinct disorders have few effective medicines ...
Voir le projet

 10

 TERMINÉ 

Towards Early diagnosis and biomarker validation in Arthritis Management (EURO-TEAM)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

An ideal intervention in a chronic inflammatory disease such as Rheumatoid Arthritis (RA) would be a preventive one. In order to develop preventive strategies and therapies two key developments need to occur: (1) Biomarkers need to be identified that can be used to predict an individual’s risk of developing RA. (2) Modifiable disease mechanisms need to be identified and characterized in the early ...
Voir le projet

 17

 TERMINÉ 

International study for treatment of childhood relapsed ALL 2010 with standard therapy, systematic integration of new agents, and establishment of standardized diagnostic and research (INTREALL)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,

Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood cancer. Given the rarity of the disease, only a large international cooperative group can recruit sufficient patients for prospective studies with specific questions in biologic subgroups. Under the umbrella of the I-BFM SG all relevant mainly European study ...
Voir le projet

 29

 TERMINÉ 

ALFRED - Personal Interactive Assistant for Independent Living and Active Ageing (ALFRED)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2016,

Description ALFRED’s objective is to develop a mobile, personalized assistant for elderly people, which helps them stay independent, coordinate with carers and foster their social contacts. ALFRED is a mobile, personalized Butler, created using cutting edge technologies such as advanced speech interaction, so you can talk directly to him. AL ...
Voir le projet

 15

 TERMINÉ 

Benchmarking Integrated Care for better Management of Chronic and Age-related Conditions in Europe (PROJECT INTEGRATE)

Date du début: 1 sept. 2012, Date de fin: 31 août 2016,

"INTEGRATE aims at gaining valuable insights into integrated care, starting from the premise that it offers benefits for patients and for Europe’s health and social security systems, which are facing the challenges of an ageing population and increased chronic conditions. For these benefits to be realised, there is still much to be learnt in terms of process design, service delivery, skills mix, p ...
Voir le projet

 10

 TERMINÉ 

Markers for Sub-Clinical Cardiovascular Risk Assessemnt (EU-MASCARA)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2016,

EU-MASCARA is a collaborative project that aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analysing a panel of biomarkers. EU-MASCARA aims to examine genetic, proteomic and metabolomic markers together with markers of inflammation, oxidative stress and cardiac remodelling to study their incremental diagnostic and predictive value over and above existi ...
Voir le projet

 16

 TERMINÉ 

ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours (ASSET)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,

Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumours (ETs) comprising neuroblastoma, medulloblastoma and Ewing sarcoma, occur early in life, and thus may reveal pathogenetically relevant lesions clearer than adulthood tumours which carry passenger mutations accumulated during life. ASSET will exploit this fact ...
Voir le projet

 20

 TERMINÉ 

EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS (ENCCA)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

"ENCCA aims to establish a durable, European Virtual Institute clinical and translational research in childhood and adolescent cancers that will define and implement an integrated research strategy and will facilitate the necessary investigator-driven clinical trials to introduce the new generation of biologically targeted drugs into standard of care for children and adolescents with cancer. This ...
Voir le projet

 34

 TERMINÉ 

Cutaneous and Mucosal HIV Vaccination (CUT'HIVAC)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,

Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cel ...
Voir le projet

 18

 TERMINÉ 

Ovarian Cancer Therapy – Innovative Models Prolong Survival (OCTIPS)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

"About 75% of advanced epithelial ovarian cancer (EOC) patients respond to first-line surgery and chemotherapy but most relapse and ultimately acquire platinum resistance which soon leads to death. Relapsed high grade serous ovarian cancer (HGSOC) is the single main cause of EOC-related morbidity and mortality (despite the fact that HGSOC is highly chemosensitive). We hypothesize that the primary ...
Voir le projet

 11

 TERMINÉ 

To decipher the optimal management of systemic sclerosis (DESSCIPHER)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2015,

The current approach to diagnosis and management of the rare disease systemic sclerosis (SSc) is based on American College of Rheumatology criteria with low sensitivity and few validated recommendations for the therapy of the disease and its manifold organ manifestations. To overcome these shortcomings, the DeSScipher project will use the multinational, prospective and open EUSTAR (Scleroderma Tri ...
Voir le projet

 15